Weight Loss Jabs Make Belts Tighter: Timpson CEO

The increasing popularity of weight-loss medications such as Ozempic and Mounjaro has led to a notable rise in people needing adjustments to their belts. James Timpson, chief executive of Timpson, observed a significant 680% jump in the number of free holes added to customers' belts this year, directly linking this to the widespread use of these drugs.

An estimated 2.4 million individuals in the UK are currently prescribed weight-loss medications. While semaglutide (marketed as Wegovy for weight loss and Ozempic for diabetes) and Mounjaro are approved, access via the NHS remains restricted, leading most patients to pay privately. The recent approval of Wegovy in a tablet form offers a new option for treatment.

Pharmacy leaders are encouraging greater efforts from the Government and NHS to expand access to these weight management treatments, particularly through community pharmacies. They highlight the transformative impact these drugs can have on health outcomes for eligible individuals and express concern over the slow NHS rollout. A wider, safer rollout via pharmacies could help mitigate the significant impact of obesity on the healthcare system.